Research
We are driving the next generation of discoveries to address critical cancer challenges and accelerate the translation of scientific evidence into patient benefit.
Education
Fostering an outstanding cancer care workforce to help maintain and enhance world-leading patient outcomes through online learning, courses and events.
Equity
Pursuing equity in access to cancer care and outcomes for all Victorians affected by cancer.
Consumer Engagement
Partnering with consumers at every step of our journey, because no-one knows cancer like someone who’s lived it.
About us
Research, academic and clinical institutions working together to accelerate cancer research, knowledge and expertise to benefit all.
News & Events
The VCCC Alliance brings you the latest in cancer research, education and clinical care through engaging, relevant and informative events.

Researcher leading innovative genetic and family cancer studies awarded 2023 Tony Burgess Medal

A University of Melbourne researcher who has provided accurate estimates of cancer risk associated with breast cancer genes is the recipient of the 2023 Tony Burgess Medal.

08 Jun 2023

A University of Melbourne researcher who has provided accurate estimates of cancer risk associated with breast cancer genes is the recipient of the 2023 Tony Burgess Medal.

Dr Shuai Li, a Senior Research Fellow at the University of Melbourne, will be officially presented with the medal on 22 June when he delivers the Tony Burgess Address on the eve of the VCCC Alliance Postdoctoral Symposium at the Melbourne Brain Centre.

Dr Li, who is also Deputy Head of the Breast Cancer Unit at the Melbourne School of Population and Global Health, topped a list of outstanding applications for the 2023 award.

VCCC Alliance Executive Director Professor Grant McArthur said:

“Dr Li’s application was a stand-out, with its strong collaborative focus, commitment to equitable care and innovative research.”

Dr Li’s research program has published the world’s largest study of the risks associated with BRCA1 and BRCA2 in 24 cancers.

“My research has provided the strongest evidence that, besides female breast and ovarian cancers, BRCA1/2 gene alterations are only associated with male breast, pancreatic, and prostate (BRCA2 only) cancers. This is a very clear message,” Dr Li said. “We also determined the most precise risk estimates for these cancers.”

His team also led the world’s most comprehensive study predicting breast cancer risk using genetics and family history.

Dr Li’s research findings have made a significant impact on clinical guidance, including being incorporated into the National Comprehensive Cancer Network (NCCN) guideline, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, for risk assessment of male breast and pancreatic cancers for BRCA1/2 mutation carriers. His findings could be used in an updated breast cancer risk model (BOADICEA), available in seven languages and used by over 9000 clinicians in more than 120 countries.

The age-specific breast cancer risk assessment data has helped design international collaborative whole-genome sequencing studies – led by the Breast Cancer Association Consortium – to search for new breast cancer genes.

Dr Li was previously the recipient of the 2018 VCCC Alliance Picchi Award for Excellence in Cancer Research.

Click here to register for the Tony Burgess Medal Ceremony and Address, to be held on the 22 June, 5.30 - 8.00 pm at the Melbourne Brain Centre.

  • University of Melbourne
  • VCCC Alliance

Get the latest in cancer news, events and more, direct to your inbox

Join a network of Victorian cancer researchers, clinicians and consumers to keep your finger on the pulse.